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Abstract
Background: Body mass index (BMI) is associated with renal disease progression in unspecified CKD. The
relationship between BMI and primary glomerular disease (GN) may be more complex. We aimed to evaluate the
association between BMI and renal disease progression in patients with primary glomerular disease (GN).
Methods: This was a single-centre retrospective cohort study performed in adult patients with biopsy-proven
primary GN (excluding minimal change disease) from January 2000 to December 2015, with follow-up data until
June 2017. BMI at time of biopsy was categorised as ≤25 kg/m2, > 25 to ≤30 kg/m2 and > 30 kg/m2. We used
univariate and multivariate survival analyses to evaluate factors associated with progression to a composite
endpoint of stage 5 CKD or renal replacement therapy (Major Adverse Renal Event - MARE) censoring for
competing risk of death using Fine and Gray subdistribution hazards model.
Results: We included 560 patients with biopsy-proven primary GN and available BMI data: 66.1% were male with
median age 54.8 (IQR 41.1–66.2) years and BMI 28.2 (IQR 24.9–32.1) kg/m2. Those with BMI 25-30 kg/m2 (n = 210)
and with BMI > 30 kg/m2 (n = 207) were older (p = 0.007) with higher systolic and diastolic blood pressures (p = 0.02
and 0.004 respectively) than those with BMI < 25 kg/m2 (n = 132). There was a greater proportion of focal segmental
glomerulosclerosis in those with higher BMI (3.9% in BMI < 25 kg/m2, 7.9% in BMI 25–30 kg/m2 and 10.7% in BMI > 30
kg/m2 of biopsies (p = 0.01)), but similar proportions of other GN diagnoses across BMI groups. Baseline eGFR (p = 0.40)
and uPCR (p = 0.17) were similar across BMI groups. There was no interaction between BMI and time to MARE (log-rank
p = 0.98) or death (log-rank p = 0.42). Censoring for competing risk of death, factors associated with progression to
MARE were: younger age, lower baseline eGFR and higher uPCR, but not BMI (SHR 0.99, 95%CI 0.97–1.01, p = 0.31) nor
blood pressure or GN diagnosis.
Conclusion: BMI was not associated with progression to MARE in this patient cohort with primary GN. Efforts should
be directed to managing other known risk factors for CKD progression.
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Background
The proportion of overweight and obese patients has in-
creased dramatically in recent years. The World Health
Organisation quotes a three-fold increase in prevalence
of obesity worldwide from 1975 to 2016 affecting up to
1.9 billion adults [1].
Body mass index (BMI) is widely and routinely used to
assess relative adiposity, categorising patients as under-
weight, normal, overweight and obese. Obese and
overweight individuals have been shown to have an in-
creased propensity to develop a multitude of comorbidi-
ties involving the cardiovascular, respiratory, endocrine,
musculoskeletal systems [2]. Obesity has also been
shown to increase mortality rates in a variety of condi-
tions [3]. There has been an increase in the proportion
of overweight or obese adults in Scotland from 1995 to
2016 (52 to 65%) [4]. Obesity is a potentially modifiable
risk factor for developing and treating these conditions.
The relationship between body weight and the kidney
appears to be more complex. Obesity is a risk factor for
incident chronic kidney disease (CKD) [5]. In two large
cohort studies, elevated BMI was an independent risk
factor for progression to both diabetic and non-diabetic
End Stage Renal Disease (ESRD) amongst adolescents
[6] and adults [7]. However, the association between
BMI and progressive renal dysfunction follows a ‘U-
shaped’ relationship with poor renal outcomes in under-
weight as well as overweight individuals [8]. Further-
more, being overweight or obese is associated with
improved outcomes in ESRD, especially in the haemodi-
alysis population. This is often referred to as the “obesity
paradox” and has been replicated in many studies [9].
Obesity is associated with specific renal pathological
changes including glomerulomegaly and thickening of
the glomerular basement membrane, which can exist
alongside other primary glomerulonephritis (GN) [10] or
progress to overt focal segmental glomerulosclerosis
(FSGS) [11]. There are some data describing outcomes
in patients with primary GN according to BMI. This is
best studied in IgA Nephropathy, where obese patients
are less likely to go into spontaneous remission and
more likely to have progressive renal disease [12–14].
Whether this is an independent effect or the result of
confounding co-factors is unclear [15, 16]. Renal biopsy
data from a Japanese registry study demonstrate that ele-
vated BMI is associated with proteinuria in minimal
change disease and membranous GN, but blood pressure
and renal function were more important predictors of
proteinuria in other glomerular diseases [17].
Managing risk factors for progression to renal endpoints
is a vital aspect of managing patients with primary GN.
Improved knowledge of the significance of these risk
factors is central to this. We aimed to analyse the relation-
ship between BMI and progression to renal endpoints in
patients with biopsy-proven primary GN. We hypothe-
sised that a higher BMI would be associated with progres-
sion of renal disease.
Methods
In this cohort study, we included all adults (age >/= 16
years) who underwent native renal biopsy in a single
centre between 01/01/2000 and 31/12/2015 with avail-
able BMI data. Follow-up data were available until 20/
06/2017. Biochemical and anthropometric data were ex-
tracted from the electronic patient record. Demographic
data included date of birth, gender and postcode.
Deprivation was estimated using the Scottish Index of
Multiple Deprivation (SIMD) in quintiles (SIMD 1 =
greatest deprivation). The SIMD is produced using Scot-
tish Government Statistics and gives a relative score of
deprivation, based on multiple indicators of poverty and
inequality for a given post code [18]. The height and
weight at the time of biopsy were collected along with
systolic and diastolic blood pressure. BMI was calculated
from the standard equation: weight (kg)/(height (me-
tres))2 and categorised into groups: BMI ≤25 kg/m2(nor-
mal weight), > 25 to ≤30 kg/m2 (overweight) and > 30 kg/
m2 (obese).
The biopsy date, indication and diagnosis were ex-
tracted. The following laboratory parameters were
collected at the time of biopsy: serum creatinine, serum
albumin, estimated glomerular filtration rate (eGFR) by
CKD-EPI and urinary protein to creatinine ratio (uPCR).
We defined the renal endpoints of interest as time
from biopsy to chronic kidney disease Stage 5 (CKD 5-
eGFR < 15 ml/min/1.73 m2) and/or renal replacement
therapy (RRT). The dates of reaching CKD 5, RRT or
death were recorded.
Patients were excluded if they had no available weight
or height records at the time of biopsy. Patients with a
primary glomerular disease were categorised as mem-
branous glomerulonephropathy (MGN), IgA nephropa-
thy (IgAN), focal segmental glomerulosclerosis (FSGS),
minimal change nephropathy (MCN) and other primary
glomerular diseases (Other) for comparison. Patients
with MCN were excluded, as this is not a progressive
condition. (Fig. 1). Patients with primary diabetic
nephropathy were excluded, but those considered to
have a primary GN and background features of diabetic
nephropathy were included.
Missing data (considered to be missing at random)
were multiply imputed by chained equations [19]. The
proportion of missing data for uPCR was 29.2%, and for
all other variables was less than 5%. Five separate
datasets were multiply imputed, and averaged across
each other, before being entered into a survival analysis.
We performed unadjusted survival analysis according
to BMI category (normal vs. overweight vs. obese) and
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compared groups using the Log-rank test. Subsequent
multivariable survival analysis was performed to evaluate
the factors independently associated with progression to
a composite renal endpoint comprising CKD 5 or renal
replacement therapy (MARE =major adverse renal
event), adjusting for the competing risk of death using
the Fine and Gray subdistribution hazards [20] and Cox
cause-specific hazards models [21]. BMI was entered
into the analyses both as a continuous variable and then
by BMI group. Pearson’s coefficient was used to assess
correlation between variables.
As a surrogate marker of fluid status (and therefore
total body weight) at time of biopsy, we assessed change
in weight after biopsy in those patients who were biop-
sied for nephrotic syndrome versus other indication. For
each patient, up to 50 post-biopsy weight recordings
were extracted. The weight closest to 6 months post-
biopsy was used to calculate change in weight. We
assumed that weight loss in the nephrotic group reflects
correction of fluid overload. Summary data are pre-
sented as mean ± standard deviation (SD) or median and
interquartile range (IQR) where data are not normally
distributed. Between group comparisons of continuous
data were evaluated using analysis of variance (ANOVA),
whilst categorical data were evaluated using Chi square
testing.
Analyses were conducted using crr, mice, riskRegres-
sion, cmprsk and cr17 packages for R statistical software.
Analyses were conducted in R Studio (version 1.0.136)
available at http://www.R-project.org and distributed
under the GNU (http://www.gnu.org) General Public
License.
Results
There were 1193 patients who underwent native renal
biopsy between 01/01/2000 and 31/12/2015: complete
BMI data were available in 1187 cases. Five hundred and
sixty patients with biopsy-proven primary GN - exclud-
ing MCN - were included (Fig. 1). Baseline characteris-
tics are described in Table 1.
There was a male preponderance (66.1%), with median
age 54.8 (41.1–66.2) years and BMI at biopsy 28.2 (24.9–
32.1) Kg/m2. Four patients were found to be underweight
(BMI < 18 kg/m2) and were included in the category of pa-
tients with BMI < 25 kg/m2 (N = 143). Those with BMI
25–30 kg/m2 (n = 210) and > 30 kg/m2 (n = 207) were
older than those with BMI < 25 kg/m2 (p = 0.007). In total
215 patients progressed to CKD 5 during follow up, 161
required RRT, and 230 patients reached CKD 5 or RRT
(MARE). The total number of patients who died during
follow up was 133.
The proportion of FSGS diagnosed increased across BMI
categories: 3.9% in BMI < 25 kg/m2, 7.9% in BMI 25–30 kg/
m2 and 10.7% in BMI > 30 kg/m2 of biopsies (p = 0.01), but
similar proportions of other GN diagnoses across the
groups (Table 2). BMI was positively correlated with sys-
tolic blood pressure (SBP) (r = 0.13, p < 0.01) and SIMD
(r = 0.13, p = 0.01), but not eGFR (r = − 0.02, p = 0.58) or
uPCR (r = 0.10, p = 0.06). There was no interaction between
BMI and time to MARE (log-rank p = 0.98) or death (log-
rank p = 0.42) (Fig. 2).
Factors associated with progression to MARE, censor-
ing for competing risk of death, included younger age
(SHR 0.99 per 1-year increase in age, 95% CI 0.97–0.99,
p = 0.01), lower eGFR (SHR 0.81 per 10ml/min/1.73m2
increase in eGFR, 95% CI 0.76–0.86, p < 0.001) and
higher uPCR (SHR 1.07 per 100 mg/mmol increase in
uPCR, 95% CI 1.02–1.11, p = 0.002). There was no
association of BMI, systolic blood pressure or primary
glomerular diagnosis with progression to MARE. Subdis-
tribution and cause-specific hazards of progression to
MARE for each factor are illustrated in Table 3.
Fig. 1 Consort diagram of included/excluded patients
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Change in weight in the 6-month period after biopsy
was greater in nephrotic (− 2.1 kg; IQR -7.35 - 1.1) ver-
sus non-nephrotic patients (+ 0.2 kg; IQR -3.3 – 3.7).
Change in weight according to BMI category (Table 4)
or GN category (Table 5) shows greater weight loss in
those with BMI > 30 kg/m2. If we assume that weight
loss in nephrotic patients represents correction of fluid
overload after biopsy, BMI category at biopsy was over-
estimated in 26 patients: 9 originally included in BMI
category 25–30 kg/m2 and 17 originally with calculated
BMI > 30 kg/m2.
Discussion
Obesity is a growing global health issue that has been
shown to impact negatively on a multitude of factors re-
garding the health and wellbeing of patients. In this sin-
gle centre study of a large cohort of patients with biopsy
proven glomerular disease, we analysed the relationship
of clinical and biological parameters with progression to
renal endpoints, with focus on BMI as a risk factor. Two
thirds of patients were overweight or obese, which is
similar to the general population from which the cohort
is derived [4]. BMI is correlated with known risk factors
for renal progression (systolic blood pressure) but is not
independently associated with progression to a com-
bined renal endpoint of CKD 5 or RRT in this patient
cohort. We have accounted for the main competing risk
(death), recognised as an important consideration in
survival analysis [22].
There are many proposed mechanisms by which obes-
ity may have a direct effect on kidney function. Some
studies have found that increasing fat consumption in
mice results in increased proteinuria, an increase in
glomerular tuft area, and mesangial expansion [23] and
associated pathophysiological findings [24]. Increased
renal blood flow in obesity has been demonstrated in
both animal [25] and human studies [26]. Others hy-
pothesise that increased adipose tissue increases circulat-
ing levels of adiponectin and leptin [27], inflammatory
proteins, oxidative stress [28], insulin and insulin resist-
ance and abnormalities in lipid metabolism [29]. These
mechanisms potentially lead to glomerular hyperfiltra-
tion, glomerular hypertension and glomerulomegaly,
thereby causing the proposed ‘obesity related glomeru-
lopathy’. We observed no significant independent impact
of BMI on renal progression in this cohort of patients
with primary GN. It may be that in clinical practice,
obesity exerts a deleterious effect on renal function via
Table 1 Summary table of baseline characteristics across BMI groups






Age (years): median (IQR) 48.1 (33.0–66.6) 55.7 (42.0–66.5) 55.0 (45.5–66.1) 54.8 (41.1–66.2)
Male (%) 61.6 72.0 63.3 66.1
BMI (kg/m2): median (IQR) 22.5 (20.9–23.8) 27.2 (26.0–28.6) 33.7 (31.6–36.8) 28.2 (24.9–32.1)
Systolic blood pressure (mmHg) 141 (23) 144 (22) 147 (21) 144 (22)
Diastolic Blood Pressure (mmHg) 75 (9) 80 (11) 82 (11) 80 (11)
eGFR (ml/min/1.73m2) 56 (38) 47 (31) 52 (34) 51 (34)
uPCR (mg/mmol): median (IQR) 318 (142–592) 317 (155–717) 400 (155–776) 337 (151–714)
Died during follow up: n(%) 40 (28.0) 50 (23.8) 43 (20.8) 133 (23.8)
RRT during follow up: n(%) 47 (32.9) 58 (27.6) 56 (27.1) 161 (28.9)
CKD 5 during follow up: n(%) 55 (38.5) 81 (38.6) 79 (38.2) 215 (38.4)
CKD 5 or RRT during follow up: n(%) 60 (42.0) 88 (41.9) 82 (39.6) 230 (41.1)
SIMD quintile: median (IQR) 2 (1–3) 2 (1–3) 2 (1–3) 2 (1–3)
BMI Body Mass Index (kg/m2), uPCR Urinary Protein Creatinine Ratio, eGFR estimated glomerular filtration rate, RRT Renal Replacement Therapy, CKD Chronic
Kidney Disease, SIMD Scottish Index of Multiple Deprivation, All data are mean (standard deviation) unless otherwise indicated
Table 2 Primary glomerular disease across BMI groups









Chi-square p= Chi-square across
groups
Membranous glomerulonephritis (%) 5.4 8.6 8.0 0.94 0.08
IgA nephropathy/HSP nephritis (%) 11.1 16.1 13.4 0.27
Focal segmental glomerulosclerosis (%) 3.9 7.9 10.7 0.01
Other primary glomerular disease (%) 5.2 5.0 4.8 0.23
BMI Body Mass Index (kg/m2), IgAN IgA Nephropathy, HSP Henoch-Schonlein Purpura
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its association with higher blood pressure, rather than
its other metabolic effects; as such strict control of
hypertension may abrogate the effect of BMI on renal
dysfunction. Similarly, various other lifestyle factors im-
portant in renal disease progression, such as physical ac-
tivity [30] [31] and smoking status [32], may be
associated with obesity; we cannot comment on such
lifestyle factors in this analysis. Obesity and the meta-
bolic syndrome, including insulin resistance and hyper-
glycaemia, is likely to play a more complex role in the
pathophysiology of diabetic nephropathy than in other
glomerulopathies. Diabetic nephropathy is the single
commonest cause of renal failure and accounts for
nearly 28% of ESRD in the Scotland [33]. Exclusion of
patients with primary diabetic and hypertensive ne-
phropathy in our study may explain the difference be-
tween the observed impact of BMI in undifferentiated
CKD and in primary GN.
It is interesting that in our cohort, FSGS is more com-
mon in patients with a BMI > 30, but that other diagno-
ses are also equally represented. This finding is
supported by recent data from Columbia University:
amongst 248 kidney biopsies performed in patients with
BMI > 40 kg/m2, obesity-related glomerulopathy (glo-
merulomegaly +/− FSGS) alone was found in 29% of pa-
tients, and the other 71% had other kidney disease
without evidence of obesity-related glomerulopathy [34].
This emphasises the importance of considering native
renal biopsy in obese patients and not assuming an
obesity-related phenomenon.
Our study has some limitations. First, BMI is a widely
used but imperfect tool to assess body fat: it does not
consider body composition (including fluid status), age
or gender, and may underestimate the obese and under-
weight categories, particularly in men [35]. Other assess-
ment tools of obesity have been proposed, such as
percentage body fat, waist circumference or hip to waist
ratio. It has been demonstrated that reported differences
between BMI and these assessments are “too small to be
of clinical relevance” and that BMI is favourable due to
the ease of collection and extraction of the data required
[36]. Second, BMI may have been overestimated in those
Fig. 2 Survival curves (a) and cumulative incidence functions (b) of time to death and major adverse renal event (MARE) according to BMI group
(1 – BMI < 25 kg/m2, 2 – BMI 25–30 kg/m2, 3 – BMI > 30 kg/m2)
Elyan et al. BMC Nephrology          (2019) 20:237 Page 5 of 7
patients with nephrotic syndrome or fluid overload.
In those patients, if the observed weight loss in the
first 6 months accurately represents fluid overload at
time of biopsy, calculated BMI would have overesti-
mated BMI category for 26 patients (9 with calculated
BMI 25-30 kg/m2 and 17 with BMI > 30 kg/m2). How-
ever, this would also have overestimated the potential
impact of BMI on renal disease and we think it un-
likely this has unduly influenced our results. Third,
we are unable to comment on the effect of being
underweight (BMI < 18 kg/m2) on renal progression
because of the small number of patients in this cat-
egory. Fourth, due to relatively small sample size, we
have combined data from patients with any primary
glomerular disease, and thus cannot comment on
whether there is any influence of BMI on progression
to renal endpoints in individual disease processes,
such as FSGS, which we have shown to be associated
with obesity. Fifth, we are unable to comment on the
degree of pathological injury (glomerulosclerosis,
interstitial fibrosis and tubular atrophy) on renal
biopsy samples, but instead have used surrogate
markers of renal injury (eGFR and proteinuria). Sixth,
due to the retrospective design of the study, there
may be other confounders for which we have not ad-
justed. Last, these findings are limited to a predomin-
antly Caucasian population.
Conclusions
In this cohort of patients with biopsy-proven primary
GN, there was no association between BMI and progres-
sion to major adverse renal event of CKD stage 5 or
requirement for renal replacement therapy. FSGS was
more common in overweight or obese patients, but
other diagnoses are equally represented; this supports
pursuit of pathological diagnosis of renal disease in
patients who are obese. Without evidence to support
weight loss in improving renal outcomes in these
patients, we recommend that clinicians focus on im-
proving management of known risk factors for renal
progression, such as hypertension, proteinuria and
smoking cessation.
Table 4 Weight and weight change at 6 months after biopsy-








Number 139 198 195 532
Weight (kg) 64.3 80.2 100.4 83.4
BMI (kg/m2) 22.1 27.4 34.9 28.8
Weight change (kg) 0.7 −0.6 −2.0 −0.8
BMI Body Mass Index (kg/m2)
Table 5 Table demonstrating average weights and weight
changes across primary glomerular disease categories
Values MGN IgAN FSGS Other All
Number 118 218 117 79 532
Weight (kg) 83.5 83.2 87.4 78.2 83.4
BMI (kg/m2) 28.9 28.3 30.2 27.7 28.8
Weight change (kg) −1.4 0.2 −1.6 −1.5 −0.8
MGN Membranous Glomerulonephritis, IgAN IgA Nephropathy, FSGS Focal
Segmental Glomerulosclerosis, Other Other Primary Glomerular Diagnosis, BMI
Body Mass Index, kg Kilogram
Table 3 Subdistribution and cause-specific hazard ratios for progression to major adverse renal event
Variable Subdistribution hazard ratio P Cause-specific hazard ratio P
Age per year increase 0.99 (0.98–1.00) 0.009 0.99 (0.98–1.00) 0.14
SBP per 10 mmHg increase 1.05 (0.98–1.11) 0.16 1.03 (0.97–1.09) 0.34
BMI (continuous– kg/m2) 0.99 (0.97–1.01) 0.31 1.01 (0.99–1.03) 0.37
BMI < 25 kg/m2 REF – REF –
BMI 25–30 kg/m2 0.90 (0.65–1.24) 0.51 0.84 (0.61–1.15) 0.27
BMI > 30 kg/m2 0.83 (0.59–1.17) 0.28 0.88 (0.63–1.22) 0.44
eGFR per 10 ml/min/1.73m2 increase 0.81 (0.75–0.86) < 0.001 0.80 (0.75–0.85) < 0.001
uPCR per 100 mg/mmol increase 1.07 (1.02–1.11) 0.002 1.06 (1.04–1.09) < 0.001
IgAN vs MGN 1.16 (0.75–1.81) 0.50 1.30 (0.85–1.97) 0.23
FSGS vs MGN 1.19 (0.77–1.84) 0.44 1.20 (0.78–1.83) 0.40
Other vs MGN 1.35 (0.83–2.18) 0.23 1.55 (0.98–2.46) 0.06
SIMD 2 vs 1 0.86 (0.62–1.18) 0.35 0.76 (0.55–1.06) 0.11
SIMD 3 vs 1 0.81 (0.54–1.21) 0.29 0.82 (0.56–1.21) 0.32
SIMD 4 vs 1 0.96 (0.63–1.46) 0.84 0.95 (0.64–1.42) 0.80
SIMD 5 vs 1 1.06 (0.67–1.66) 0.81 1.12 (0.73–1.72) 0.60
BMI Body Mass Index, eGFR estimated glomerular filtration rate, MGN Membranous Glomerulonephritis, IgAN IgA Nephropathy, FSGS Focal Segmental
Glomerulosclerosis, Other Other Primary Glomerular Diagnosis, uPCR Protein Creatinine Ratio, SIMD Scottish Index of Multiple Deprivation
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segmental glomerulosclerosis; GN: Glomerulonephritis; MARE: Major adverse
renal event; MCN: Minimal change nephropathy; MGN: Membranous
glomerulonephropathy; RRT: Renal replacement therapy; SIMD: Scottish Index
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